For colorectal adenomas, biennial screening increases diagnosis rates
the ONA take:
According to findings presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, screening patients biennially for colorectal cancer in a region of France increased the rate of diagnosis of high-risk polyps by 89%. Polyps, or adenomas, are pre-cancerous and a risk factor for developing colorectal cancer.
For the study, researchers identified patients aged between 50 and 74 years who were diagnosed with their first adenoma between 1997 and 2008. Of those, 38.7% had high-risk polyps. They found that the rate of diagnosis of pre-cancerous adenomas increased by 89% after the initiation of fecal occult blood testing. The rate of diagnosis of non-advanced adenomas increased by 68%.
The authors suggest that these results demonstrate that patients should be routinely screened for colorectal cancer as increased participation will improve success of screening programs.
Screening patients biennially for colorectal cancer increased rate of diagnosis by 89%.
The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk pre-cancerous adenomas (sometimes called polyps) by 89%, researchers have reported at the ESMO 2014 Congress in Madrid. Dr Vanessa Cottet from INSERM Unité 866 in Dijon, France, and colleagues studied the region of Côte-d'Or, where a registry has been collecting data on adenomas since 1976.
They wanted to evaluate the rate of diagnosis of adenomas before and after the initiation of a screening program using fecal occult blood testing that began in 2003. The study included all residents aged between 50 and 74 years of age who had a first adenoma identified between January 1997 and December 2008.
The researchers showed that 38.7% of these people had high-risk adenomas - meaning they were larger than 1 centimetre in diameter, involved the finger-like projections called villi in the intestinal lining, or exhibited a high grade of dysplasia.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|